The drug SI-B001 shows an significant step forward in the care of difficult-to-treat multiple myeloma. The unique antibody specifically targets BCMA on myeloma tumors, triggering BCMA-dependent cellular cytotoxicity while eliciting tumor-killing body's responses. Preliminary clinical data suggest… Read More